ロード中...
Multicenter Assessment of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer
BACKGROUND: The efficacy of neoadjuvant chemotherapy (NAC) for muscle-invasive bladder cancer (BCa) was established primarily with methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC), with complete response rates (pT0) as high as 38%. However, because of the comparable efficacy with better...
保存先:
| 出版年: | Eur Urol |
|---|---|
| 主要な著者: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
2014
|
| 主題: | |
| オンライン・アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4840190/ https://ncbi.nlm.nih.gov/pubmed/25257030 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.eururo.2014.09.007 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|